Latest BVF INC/IL Stock Portfolio
BVF INC/IL Performance:
2025 Q4: 35.9%YTD: 18.34%2024: -3.59%
Performance for 2025 Q4 is 35.9%, and YTD is 18.34%, and 2024 is -3.59%.
About BVF INC/IL and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, BVF INC/IL reported an equity portfolio of $3 Billions as of 31 Dec, 2025.
The top stock holdings of BVF INC/IL are KYMR, RVMD, MLTX. The fund has invested 14.4% of it's portfolio in KYMERA THERAPEUTICS INC and 9% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off PROTAGONIST THERAPEUTICS INC (PTGX), CIDARA THERAPEUTICS INC (CDTX) and CELCUITY INC (CELC) stocks. They significantly reduced their stock positions in AXSOME THERAPEUTICS INC (AXSM), SEPTERNA INC and TYRA BIOSCIENCES INC (TYRA). BVF INC/IL opened new stock positions in DISC MEDICINE INC and INVIVYD INC (ADGI). The fund showed a lot of confidence in some stocks as they added substantially to XENCOR INC (XNCR), CRESCENT BIOPHARMA INC. and COMPASS THERAPEUTICS INC (CMPX).
The top stock holdings of BVF INC/IL are KYMR, RVMD, MLTX. The fund has invested 14.4% of it's portfolio in KYMERA THERAPEUTICS INC and 9% of portfolio in REVOLUTION MEDICINES INC.
The fund managers got completely rid off PROTAGONIST THERAPEUTICS INC (PTGX), CIDARA THERAPEUTICS INC (CDTX) and CELCUITY INC (CELC) stocks. They significantly reduced their stock positions in AXSOME THERAPEUTICS INC (AXSM), SEPTERNA INC and TYRA BIOSCIENCES INC (TYRA). BVF INC/IL opened new stock positions in DISC MEDICINE INC and INVIVYD INC (ADGI). The fund showed a lot of confidence in some stocks as they added substantially to XENCOR INC (XNCR), CRESCENT BIOPHARMA INC. and COMPASS THERAPEUTICS INC (CMPX).
BVF INC/IL Annual Return Estimates Vs S&P 500
Our best estimate is that BVF INC/IL made a return of 35.9% in the last quarter. In trailing 12 months, it's portfolio return was 18.34%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| disc medicine inc | 51,616,500 |
| invivyd inc | 48,226,800 |
New stocks bought by BVF INC/IL
Additions
| Ticker | % Inc. |
|---|---|
| xencor inc | 160 |
| crescent biopharma inc. | 98.06 |
| compass therapeutics inc | 63.47 |
| stoke therapeutics inc | 36.73 |
| annexon inc | 30.4 |
| nektar therapeutics | 22.17 |
| structure therapeutics inc | 8.59 |
| avalo therapeutics inc | 0.00 |
Additions to existing portfolio by BVF INC/IL
Reductions
| Ticker | % Reduced |
|---|---|
| axsome therapeutics inc | -90.6 |
| septerna inc | -57.15 |
| tyra biosciences inc | -41.7 |
| monte rosa therapeutics inc | -32.23 |
| palvella therapeutics inc ne | -24.3 |
| revolution medicines inc | -15.55 |
| abivax sa | -8.96 |
| immunocore hldgs plc | -5.42 |
BVF INC/IL reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| essa pharma inc | -2,228,680 |
| protagonist therapeutics inc | -170,122,000 |
| cidara therapeutics inc | -135,420,000 |
| sab biotherapeutics inc | -1,874,720 |
| celcuity inc | -32,526,000 |
| nls pharmaceutics ltd | -262,927 |
| forte biosciences inc | -980,250 |
BVF INC/IL got rid off the above stocks
Sector Distribution
BVF INC/IL has about 68.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 68.9 |
| Others | 29.4 |
| 1.6 |
Market Cap. Distribution
BVF INC/IL has about 9% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- UNALLOCATED
- MID-CAP
- LARGE-CAP
- MICRO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 37.6 |
| UNALLOCATED | 29.4 |
| MID-CAP | 18.7 |
| LARGE-CAP | 9 |
| MICRO-CAP | 5.3 |
Stocks belong to which Index?
About 58.9% of the stocks held by BVF INC/IL either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 58.9 |
| Others | 41.1 |
BVF INC/IL Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of BVF INC/IL
BVF INC/IL has 41 stocks in it's portfolio. About 62.8% of the portfolio is in top 10 stocks. XOMA proved to be the most loss making stock for the portfolio. was the most profitable stock for BVF INC/IL last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACIU | ac immune sa | 2.10 | 19,822,400 | 62,242,400 | unchanged | 0.00 | ||
| ADGI | invivyd inc | 1.62 | 19,525,000 | 48,226,800 | new | |||
| ANNX | annexon inc | 1.54 | 9,128,080 | 45,823,000 | added | 30.4 | ||
| AVTX | avalo therapeutics inc | 0.83 | 1,355,260 | 24,611,500 | added | 0.00 | ||
| AXSM | axsome therapeutics inc | 0.28 | 45,757 | 8,357,060 | reduced | -90.6 | ||
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CELC | celcuity inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics inc | 2.00 | 5,750,680 | 59,519,600 | unchanged | 0.00 | ||
| CMPX | compass therapeutics inc | 1.40 | 7,764,840 | 41,697,200 | added | 63.47 | ||
| ELDN | eledon pharmaceuticals inc | 0.32 | 6,293,280 | 9,502,860 | unchanged | 0.00 | ||
| EPIX | essa pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FBRX | forte biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FDMT | 4d molecular therapeutics in | 1.17 | 4,629,290 | 34,719,700 | unchanged | 0.00 | ||
| FHTX | foghorn therapeutics inc | 0.96 | 5,302,000 | 28,630,800 | unchanged | 0.00 | ||
| GHRS | gh research plc | 3.77 | 8,827,710 | 112,112,000 | unchanged | 0.00 | ||
| GLUE | monte rosa therapeutics inc | 2.02 | 3,835,890 | 60,146,700 | reduced | -32.23 | ||
| IKNA | imagenebio inc | 0.19 | 802,102 | 5,534,500 | unchanged | 0.00 | ||
| IMCR | immunocore hldgs plc | 1.69 | 1,488,980 | 50,293,900 | reduced | -5.42 | ||
| IMUX | immunic inc | 0.14 | 7,652,970 | 4,084,390 | unchanged | 0.00 | ||
| IVA | inventiva sa | 0.11 | 686,040 | 3,190,090 | unchanged | 0.00 | ||